We have employed a neutralizing monoclonal antibody, prepared against the Mr 74,000 cholesteryl ester transfer protein (CETP), to investigate the regulation of lecithin:cholesterol acyltransferase (LCAT) activity by cholesteryl ester (CE) transfer, and also to determine which lipoproteins are substrates for LCAT in hum.n plasma. The incubation of normolipidemic plasma led to transfer of CE from HDL to VLDL, and of triglycerides from VLDL to LDL and HDL. This net mass transfer of neutral lipids between the lipoproteins was eliminated by the monoclonal antibody. However, CE transfer inhibition had no effect on the rate of plasma cholesterol esterification in plasma incubated from 10 min to 24 h at 370C. In the absence of CE transfer, HDL and LDL exhibited cholesterol esterification activity, whereas VLDL did not. The rate of CE formation in HDL was three to four times greater than in LDL during the first hour of incubation, but CE formation in HDL decreased after 6-8 h, while that in LDL continued. Thus, (a) the Mr 74,000 CETP is responsible for all neutral lipid mass transfer in incubated human plasma, (b) the rate of CE formation in plasma is not regulated by CE transfer from HDL to other lipoproteins, and (c) HDL is the major initial substrate for LCAT; LDL assumes a more significant role only after prolonged incubation of plasma.
Introduction
Cholesteryl esters (CE)' are actively formed and redistributed among lipoproteins in human plasma. Cholesterol is esterified in plasma by the action of lecithin:cholesterol acyltransferase (LCAT, EC 2.3.1.43) (1, 2) , then the CE is redistributed among lipoproteins by lipid transfer processes. Nichols et al. (3, 4) first reported the net transfer of CE and triglycerides between lipoproteins in incubated plasma. Using reconstituted lipopro-teins, proteins purified from plasma were subsequently shown to promote the reciprocal transfer of triglycerides and CE between triglyceride-rich lipoproteins and HDL particles (5) (6) (7) (8) .
Although the neutral lipid transfer activity of these protein preparations has been shown using isotopic and mass assays in reconstituted systems, there has been no direct evidence linking the activity of a specific lipid transfer protein with the exchange of CE and triglycerides exhibited in whole plasma.
Recently, an Mr 74,000 cholesteryl ester transfer protein (CETP) has been purified from human plasma (9) , and used to prepare monoclonal antibodies (10) . These monoclonal antibodies were found to inhibit completely the CE and triglyceride transfer activities, and partially inhibit phospholipid transfer activity in human plasma. However, these experiments employed radioassays to measure transfer activities and did not directly demonstrate that mass transfer of neutral lipids in incubated plasma was due only to the Mr 74,000 CETP. One of the CETP monoclonal antibodies, TP2, formerly 5C7 (10) , is used in the present study to demonstrate the role of CETP in the mass transfer of neutral lipids in 'human plasma. Previous studies have suggested that LCAT activity may be regulated by the rate of CE transfer from HDL to other lipoproteins (1 1, 12) . The addition of purified CETP was found to increase cholesterol esterification in an in vitro system consisting of purified enzyme, lecithin, and sphingomyelin liposomes (CE donor and acceptor particles, respectively) (11) .
Although the accumulation of newly esterified cholesterol in plasma is accompanied by a decrease in the rate of CE formation (12) , there has not been any direct evidence that the transfer of CE out of HDL is the regulatory step for cholesterol esterification. The neutralizing antibody, TP2, thus, provided a tool to determine if CETP regulates LCAT activity in plasma. Moreover, the ability to inhibit CETP activity allowed us to examine the relative importance of LDL and HDL as substrates for the plasma LCAT reaction.
Methods Materials [7- 
Subjects
Healthy, 12-h fasting human subjects were used as blood donors (Table  I ). Blood was collected into tubes containing sodium EDTA. Plasma was immediately separated at 4VC by centrifugation and collected. The anti-protease, aprotinin (0.14 TIU/ml plasma), was added to all plasma samples before use in experiments.
Inhibition ofneutral lipid transfer
Monoclonal antibodies were prepared against partially purified human CETP, as described previously (10) . Three monoclonal antibodies were found to be similarly effective in inhibition of neutral lipid transfer. One of these monoclonal antibodies, TP2 (formerly 5C7), was used in the present investigations. Previously (10), nonspecific, monoclonal IgG was found to have no effect on CETP activity in human plasma, and therefore was not used in the current study.
[3H]Cholesterol-labeling ofplasma samples 
Incubation
Plasma or [3H]cholesterol-labeled plasma was incubated at 370C for 24 h in the absence or presence of monoclonal antibody, TP2 (13.5 sg protein/ml plasma). The volume of the sample incubated varied from 2 to 4 ml. Some samples were also incubated in the presence of 2 mM E600, an LCAT inhibitor. Since LCAT (14) and CETP (15) activities are essentially inactive at 4VC, corresponding samples incubated at 4VC served as controls. Aliquots were collected at selected time intervals, and analyzed as described below.
Assay ofCE transfer activity
The CE transfer activity was measured in plasma using a radioassay described previously (16) . Plasma (20 ll 
Compositional analysis
Free cholesterol (310-328), total cholesterol (237-574), and triglycerides (877-557) were analyzed using enzymatic kits from Boehringer Mannheim Diagnostics. The triglyceride kit measured triglycerides after conversion of any free glycerol in the sample to an inactive product. To analyze small amounts of sample (5-20 Ml), the amount of enzymatic reagent was decreased proportionally in all enzymatic kits.
Standards for the assays were also obtained from Boehringer. Phospholipids were measured according to the method of Bartlett (19) . The Lowry assay (20) was used to determine protein, using BSA as the standard.
Statistical analysis
Paired t test (two-tailed) was used to determine statistical significance. All data are expressed as mean+SEM, unless otherwise indicated.
Results
Effect of TP2 on mass transfer ofcholesteryl esters and triglycerides in plasma. The goal of the initial experiments was to determine ifthe monoclonal antibody, TP2, caused inhibition of neutral lipid transfer in human plasma. Using an isotopic assay, we found inhibition of99%±6.9% ofplasma CJ transfer activity, similar to the previous report (10) . To Incubation Time (h) Figure 1 . LCAT activity in plasma incubated in the presence or absence of CE transfer. Fresh human plasma (2 ml) obtained from fasting subjects (n = 7) was incubated for 24 (solid bar) CETP activity; the symbols above the bars indicate significant differences between samples incubated with and without CETP activity (Fig. 2) . With CETP active, there were net increases of CE mass in VLDL, LDL, and HDL, reflecting the combined activities of LCAT and CETP (Fig. 2 A) . When transfer activity was inhibited, and only cholesterol esterification was active, CE accumulated in LDL, as well as HDL, but not in VLDL. This indicates that the CETP transfers CE from HDL to VLDL, as in the LCAT-inhibited state (Table II) . The results also show that since the increase in LDL CE in plasma without CETP activity cannot be due to transfer, LDL also serves as a direct substrate for LCAT. Again, triglyceride transfer from VLDL to LDL and HDL was abolished by inhibition of CETP (Fig. 2 B) . Since LCAT activity was not associated with VLDL, the accumulation of CE in VLDL was due solely to transfer. We found no significant difference between net mass transfer of CE to VLDL in plasma samples incubated with inactive LCAT (0.09±0.066 mg CE transferred/ml plasma per 24 h, Table II ), and that in corresponding samples (same subjects) incubated with active LCAT (0.073±0.055 mg CE transferred/ml per 24 h, Fig. 2 A) . This suggests that in normolipidemic plasma incubated for 24 h, neutral lipid transfer is not influenced by LCAT action.
After incubation of plasma at 37°C, the amount of free cholesterol declined in all lipoprotein classes, as expected for continued LCAT action (Fig. 2 C) . The decrease was greatest in LDL, demonstrating that LDL provides the major source of free cholesterol for the LCAT reaction, as previously described (12) . VLDL free cholesterol did decline slightly when CETP was active. VLDL phospholipid was also decreased with CETP active (Fig. 2 D) . However, there was no decline in either free cholesterol or phospholipid in VLDL from plasma incubated with CETP inactive, consistent with the CETP playing a role in transfer of phospholipids from VLDL to other lipoproteins. The changes in free cholesterol in VLDL may have been secondary to the changes in VLDL phospholipid, since phospholipid enrichment of lipoproteins in plasma has been shown to be accompanied by an enrichment in unesterified cholesterol (2 1).
Sites ofcholesterol esterification in human plasma. The use of TP2 to inhibit CE transfer also allowed us to determine the sites of cholesterol esterification in plasma. The results of the 24-h incubation (Fig. 2) indicated that both LDL and HDL may be important substrates for LCAT.2 To determine if LDL was an important substrate for LCAT over the entire 24-h time period, CE formation in lipoproteins was followed over time by measuring the accumulation of esterified [3H]cholesterol in the HDL and VLDL + LDL fractions. With CETP inactive, any CE accumulation in the lipoprotein fractions was due to action of LCAT on that specific fraction. It was observed previously (Fig. 2) that there was no CE accumulation in VLDL over time, so any increase of CE in the VLDL + LDL fraction was solely in LDL. Although the amount of esterified [NH]-cholesterol increased immediately in both HDL and LDL fractions in plasma without CETP activity, the rate of cholesterol esterification was three to four times greater on HDL than on LDL during the first 2 h of incubation (Fig. 3 A) . Upon further incubation, the rate of CE formation in the HDL began to decline after 4-6 h incubation, while that of LDL continued to increase. With CETP active, a larger amount of [3H]CE appeared in LDL and VLDL, reflecting transfer from site of formation in HDL to CE acceptor lipoproteins (Fig.  3 B) .
Correlational analyses: effect oflipoprotein mass ratios on LCAT and lipid transfer activities. A significant correlation was found between the accumulation of CE in LDL after 24 h incubation, when CETP was inhibited, and LDL CE/HDL CE (r = 0.621, P < 0.005), suggesting that distribution of LCAT activity in incubated plasma can be determined by the relative masses of LDL and HDL. Accumulation of CE in HDL demonstrated no significant correlation with any of the variables measured.
Plasma triglyceride levels correlated inversely with HDL CE (r = -0.797, P < 0.001), which agrees with previous reports (24) (25) (26) . With CETP active, strong positive correlations were obtained between transfer ofCE to VLDL and the following: VLDL triglycerides (Fig. 4 , r = 0.948, P < 0.001), VLDL triglycerides/HDL CE (r = 0.916, P < 0.001), and VLDL triglycerides/LDL CE + HDL CE (r = 0.861, P < 0.001). When the CETP was inactive, there was no longer any correlation 2. It is conceivable that the presence of the TP2 may have induced association of LCAT, along with CETP, with LDL. This, in turn, would result in increased CE formation in the LDL fraction. To test this, LCAT activity, or formation of [3H]cholesteryl esters, was measured in lipoproteins fractions of [3Hlcholesterol-labeled plasma, isolated using a Sepharose CL-6B column, as described previously (22) . The majority of LCAT activity remained on HDL, similar to that previously described (23) , and the presence of the TP2 in plasma did not appear to shift LCAT onto LDL (data not shown). Aliquots were change of CE and triglycerides (7) (8) (9) 27) , and even net transfer during the inof neutral lipids (5, 8, 9, 28) Fig. 1 .
of CE acceptor lipoproteins is a major determinant of the amount of net neutral lipid transfer (Fig. 4) , as previously postulated (29 (12) . In contrast, CE transfer from VLDL to HDL was more iereas that of pronounced with active LCAT in an earlier study (34). How-*h incubation ever, this was observed under hypertriglyceridemic conditions in a recombinant system of high levels of VLDL from an LCAT-deficient patient and HDL from a normal subject. In addition, this study used p-chloromercuri-phenyl sulfonate, which is now known to be a neutral lipid transfer inhibitor (35) , as well as an LCAT inhibitor. Thus, the slower transfer in the LCAT inhibited plasma may have been due to a direct effect of p-chloromercuriphenyl sulfonate on CETP. Our results suggest that in normolipidemic plasma, LCAT does not play an important role in determining CE transfer rate.
The relative importance of the different lipoproteins as substrates for LCAT in plasma has been somewhat controversial. The ability to inhibit neutral lipid transfer in human plasma permitted a new and direct approach to investigate the ------------°-question of which lipoproteins accumulate CE and therefore serve as the native substrate for LCAT in human plasma. A dominant role of HDL and a lesser role of LDL as LCAT 0. 8 1 substrate has been demonstrated in earlier studies, which used ultracentrifugally isolated lipoproteins (36, 37) . However, a rcerides. A recent study using pig plasma, which lacks neutral lipid the presence transfer activity, has suggested that LDL is the major substrate vity (from Fig. for LCAT (38) . The conclusion that the majority of newly mple.
formed CE was on pig LDL was based on data largely derived from plasma incubated for long periods of time. The results obtained in the present study clearly show that HDL is the primary substrate for the initial LCAT reaction in whole human plasma. LDL is a minor initial substrate, but becomes more important with continued incubation of plasma. An unexpected finding in the present study was that neither the initial rate of CE formation, nor the accumulation of CE over the 24-h incubation was affected by the blockade of neutral lipid transfer in incubated plasma. Previous investigations suggested that CE transfer between lipoproteins is limiting for cholesterol esterification, based on in vitro incubations using vesicular lipoprotein particles (11) . In whole plasma, native, spherical lipoproteins may have greater flexibility to accomodate CE, products of the LCAT reaction, without adversely influencing LCAT activity. Also, we showed that LDL can assume a significant role as an LCAT substrate when CE formation becomes limited in HDL (i.e., after 6-8 h incubation). This versatility of LDL as an alternative site for LCAT reaction may allow the total plasma LCAT activity to remain the same, even during prolonged incubation of plasma with CETP inactive. The decline in HDL CE formation after 6-8 h incubation (Fig. 3 ) may have reflected product inhibition in HDL, and/or depletion ofavailable substrates in HDL, leading to the subsequent shift of cholesterol esterification from HDL to LDL.
Our findings have implications for the role of CETP in reverse cholesterol transport, a pathway postulated to be antiatherogenic. In one version ofthis theory, cholesterol diffuses from tissues into HDL, is esterified by LCAT action, and then transferred to VLDL for ultimate removal by the liver (39) . In tissue culture experiments, plasma LCAT activity promotes removal of free cholesterol and CE from cells (40) . If the CE transfer process was able to drive the LCAT reaction, this would imply indirect regulation of tissue cholesterol removal by CETP. The lack of effect of CETP on cholesterol esterification indicates that this mode of regulation is unlikely to occur in human plasma. However, CETP does influence the transfer of CE from HDL to triglyceride-rich lipoproteins, and this may ultimately influence the rate of transfer of CE from plasma to the liver.
